Clinical Trial VICCHEM1336


A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy

Principal Investigator(s)

Stephen Strickland


  • Protocol No. VICCHEM1336
  • Open Date: 12/09/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To assess the safety and tolerability of eltrombopag versus placebo in subjects receiving standard induction therapy for acute myeloid leukemia (AML)
  • Disease Sites: Leukemia
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Cytarabine (ARA-C); Daunorubicin (Daunomycin); Eltrombopag
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01890746
  • Secondary Protocol No: TRC117146



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.